ライフサイエンスコーパス: pharmacoeconomic

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 levels and reinforces the need to undertake pharmacoeconomic analyses and choose therapies from a lo

2 Pharmacoeconomic analyses of chemotherapeutic options co

3 e of the different costs of the antifungals, pharmacoeconomic analysis is required to identify the mo

4 We conducted a pharmacoeconomic analysis to determine whether the alter

5 To describe pharmacoeconomics and its relationship to drug intervent

6 f IVIG, combined with a dose-finding effect, pharmacoeconomics, and quality-of-life assessments, are

7 Pharmacoeconomics appear to play a dominant role in rheu

8 ogy, pharmacokinetics, pharmacodynamics, and pharmacoeconomics complements the expertise of other mem

9 But to some extent these pharmacoeconomic concerns are amplified in myeloma due t

10 pofol; benzodiazepines; intensive care unit; pharmacoeconomics; critical illness

11 intervention is prohibitive, as supported by pharmacoeconomic data, commentary might be provided.

12 so widely variable and there is a paucity of pharmacoeconomic data, the JTFPP generally does not cons

13 so widely variable and there is a paucity of pharmacoeconomic data, the JTFPP generally does not cons

14 tiveness analysis, the preferred approach to pharmacoeconomic evaluation today.

15 Pharmacoeconomic evaluations are crucial to the optimal

16 Pharmacoeconomic evaluations are increasingly important

17 toid arthritis, there is growing interest in pharmacoeconomic evaluations in other rheumatic diseases

18 of the chronic nature of rheumatic diseases, pharmacoeconomic evaluations must be carried out over su

19 The critical assessment and utilization of pharmacoeconomic evaluations, always in context with cur

20 o measure both the clinical efficacy and the pharmacoeconomic impact of implementing, as standard of

21 g with associated increases in mortality and pharmacoeconomic impact.

22 Pharmacoeconomics is assuming an increasingly important

23 Pharmacoeconomics is the branch of economics which appli

24 in contemporary oncology practice, driven by pharmacoeconomic issues, patient convenience, and the po

25 The purpose of this study was to compare the pharmacoeconomics of liposomal versus conventional thera

26 We examine current myeloma therapy from a pharmacoeconomic perspective, and discuss the costs invo

27 The pharmacoeconomic principles that drive oral drug formula

28 sions about a sponsor's proprietary agent in pharmacoeconomic studies.

29 Long-term functional and, ultimately, pharmacoeconomic, studies in elderly persons are indicat

30 Our results provide pharmacoeconomic support for the use of lamivudine proph

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。